Zobrazeno 1 - 10
of 20
pro vyhledávání: '"Paul C. Lobben"'
Autor:
Andrew D. Campbell, Rubén Haro, Thomas Andrew Brandt, Melodie Christensen, David B. Damon, Ke Wang, Carolina Alhambra, Paul C. Lobben, Jacob M. Janey, J. Eugenio de Diego, Ling Li, Iulia I. Strambeanu, Susana García-Cerrada, Javier Magano, Emma McInturff, Steven M. Mennen, Jack Twilton, David W. C. MacMillan, Fangfang Liu, Jesús Castañón, Matthew A. Zajac, Pablo Garcia-Losada, Sebastien Monfette, Mario Barberis, Alan H. Cherney, Jason M. Stevens, Barbara J. Sitter, Danielle M. Schultz, Ronald J. Post, Simon Berritt, C. Liana Allen, David C. Leitch
Publikováno v:
Organic Process Research & Development. 23:1213-1242
High-throughput experimentation (HTE) has revolutionized the pharmaceutical industry, most notably allowing for rapid screening of compound libraries against therapeutic targets. The past decade ha...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7d057d4265eaefcd550f067f2a336489
https://doi.org/10.1021/acs.oprd.9b00140
https://doi.org/10.1021/acs.oprd.9b00140
Autor:
Thomas M. Razler, Jianji Wang, Yi Hsiao, Yuping Qiu, Thorsten Rosner, Kolotuchin Sergei, Carolyn S. Wei, Carrasquillo Ronald, Andrew G. Lee, Brendan Mack, Paul C. Lobben, Jacob M. Janey, Zhongping Shi, Eric M. Simmons, Jason M. Stevens, Xinhua Qian, Eric C. Huang, Federico Lora-Gonzalez, Thomas La Porte, Steven R. Wisniewski, Geng Peng, Gregory L. Beutner, Boguslaw Mudryk, Kishta Katipally, Ye Zhu, Antonio Ramirez
Publikováno v:
Organic Letters. 20:3736-3740
A strategy to prepare compounds with multiple chirality axes, which has led to a concise total synthesis of compound 1A with complete stereocontrol, is reported.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0b68020a70953f67cf64673382d9733e
https://doi.org/10.1021/acs.orglett.8b01218
https://doi.org/10.1021/acs.orglett.8b01218
Autor:
Dawn Sun, Kristen N. Ryan, Daniel Smith, Subramaniam Krishnananthan, Min Hu, Dauh-Rurng Wu, Wenge Cui, Paul C. Lobben, Arvind Mathur, Shuang Liu, Jennifer Naginskaya, Richard E. Olson, Peng Li, Jianqing Li, Alicia Ng
Publikováno v:
Tetrahedron: Asymmetry. 28:196-202
BMS-911278 was identified as a potent triple reuptake inhibitor potentially useful for the treatment of depression. The original racemic synthesis suffered from tedious and low recovery resolution and HPLC separation, as well as low-yielding hazardou
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cd99d111ddccc082e4c2c89c67ec4c3f
https://doi.org/10.1016/j.tetasy.2016.12.003
https://doi.org/10.1016/j.tetasy.2016.12.003
Autor:
Yuh-Lin Yang, Min Hu, Shuang Liu, Brandon Miles, Bingidimi I. Mobele, Wenge Cui, Richard E. Olson, Rulin Zhao, Kassoum Nacro, Matthew Isherwood, Bei Wang, Paul C. Lobben, Rasidul Amin, Bang-Chi Chen
Publikováno v:
Organic Process Research & Development. 20:44-50
Herein, we describe the enabling synthesis of (+)-BMS-820836, a 4,7-disubstituted tetrahydroisoquinoline which was developed as a treatment for a range of neurological diseases, including depression and neurophatic pain. In order to advance the drug
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2f8aad4c7ab58a16fd03472a1a59ee37
https://doi.org/10.1021/acs.oprd.5b00261
https://doi.org/10.1021/acs.oprd.5b00261
Autor:
Richard J. Fox, Michael B. Hay, Gregory L. Beutner, Keming Zhu, Carolyn S. Wei, Lopa Bakrania, Cuniere Nicolas, Christopher S. Regens, Fanfair Dayne Dustan, Martin D. Eastgate, Chester E. Markwalter, Kristy Tran, Neil A. Strotman, Yi Hsiao, Michael Lawler, Maxime Soumeillant, Dimitri Skliar, Thorsten Rosner, Benjamin M. Cohen, Paul C. Lobben
Publikováno v:
The Journal of organic chemistry. 84(8)
The development of an improved short and efficient commercial synthesis of the JAK2 inhibitor, a complex pyrrolopyridine, BMS-911543, is described. During the discovery and development of this synthesis, a Pd-catalyzed C–H functionalization was inv
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d2f077ef70cb94bf27825edbeeef9c53
https://pubmed.ncbi.nlm.nih.gov/30388009
https://pubmed.ncbi.nlm.nih.gov/30388009
Autor:
Steve S. Y. Wang, Paul C. Lobben, Jale Muslehiddinoglu, Laporte Thomas L, Lori Spangler, Steven H. Chan, Mourad Hamedi
Publikováno v:
Organic Process Research & Development. 18:1492-1502
A thermal runaway potential was identified for the conversion of a tertiary alcohol to a hydroxypyrrolotriazine intermediate in the synthesis of brivanib alaninate. A continuous process was developed to mitigate the potential thermal runaway and allo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::296fe59b7156729816ad4e8e10d9a060
https://doi.org/10.1021/op500176z
https://doi.org/10.1021/op500176z
Autor:
Martin D. Eastgate, Fanfair Dayne Dustan, Lopa V. Desai, Eric M. Anderson, Paul C. Lobben, Gregory L. Beutner, Simon Leung
Publikováno v:
Organic Process Research & Development. 18:1812-1820
Herein we report a novel heterogeneous pyrrole nitration that can be run on a large scale in batch mode. Activation of sodium nitrate by SO3–pyridine in acetonitrile leads to the formation of an insoluble nitronium sulfate intermediate that effects
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b239a23d5de479baa4d11529799c82c0
https://doi.org/10.1021/op5001572
https://doi.org/10.1021/op5001572
Autor:
Daniel Wasser, Zhongmin Xu, Robert Wethman, Alan Braem, John M. Wasylyk, Shih-Ying Chang, Fernando Quiroz, David K. Leahy, James S. Bergum, Nathaniel Kopp, Paul C. Lobben, Jale Muslehiddinoglu, Laporte Thomas L, Dimitri Skliar, Evan Barlow, Frank Gibson, Lori Spangler, Chiajen Lai, Sushil K. Srivastava
Publikováno v:
Organic Process Research & Development. 19:900-907
This manuscript describes the control strategy for the commercial process to manufacture brivanib alaninate. The active pharmaceutical ingredient is a prodrug which is susceptible to hydrolysis. In addition to controlling hydrolysis, a robust strateg
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::80ca7ba371a88f12f41ba7f1fa8ce8fe
https://doi.org/10.1021/op500126u
https://doi.org/10.1021/op500126u
Autor:
Gerard A. Crispino, Paul C. Lobben, Laporte Thomas L, Christos G. Papaioannou, Frederic G. Buono, Frank Gibson, Jaan A. Pesti, John E. Thornton, Lori Spangler
Publikováno v:
Organic Process Research & Development. 18:89-102
The development of a practical, commercial process for the preparation of 4-fluoro-2-methyl-indol-5-ol and its subsequent coupling with a pyrrolotriazine to form an advanced intermediate of the oncology therapy brivanib alaninate is described. A key
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a58fb34d4462fe999f14ba5f21d4537a
https://doi.org/10.1021/op400242j
https://doi.org/10.1021/op400242j
